Bowel cancer patients currently face six months of gruelling chemotherapy after surgery, but a new trial enrolling over 9,000 people across the UK will test whether three months works just as well. This matters because bowel cancer recurs in one out of every two patients after surgery, and the side effects of chemotherapy—fatigue, nerve damage, nausea—worsen the longer treatment continues. Past evidence hints that a shorter course might offer the same survival benefit, but no direct head-to-head comparison on this scale has ever been done. The trial randomly assigns half the patients to three months of chemotherapy and half to the standard six months, then tracks them for years to measure cancer recurrence, side effects, quality of life, and treatment costs. If three months proves equally effective, the change would be immediate and concrete: patients would endure half the side effects, spend less time in hospital, and return to normal life sooner. For the NHS, shorter treatment would free up chemotherapy slots and reduce drug costs, making the entire care pathway more efficient. This is not fundamental science—it is a pragmatic, large-scale test of a treatment schedule that could directly reshape standard practice for tens of thousands of patients each year.
View original technical description
Bowel cancer is a common disease. Most patients will have an operation to remove the cancer. Unfortunately the cancer will come back in 1 out of 2 patients. There is evidence to suggest that a 6-month course of chemotherapy can reduce the chance of the cancer coming back by killing the cancer cells that may have been left behind after surgery. In the past, patients have received 6 months of chemotherapy treatment. Chemotherapy has side effects and many of these side effects get worse as the treatment goes on. There is some evidence that 3 months treatment provides the same benefit as 6 months, but this has never been directly compared. The aim of this study is to find out if 3 months of chemotherapy is just as effective as 6 months, with fewer side effects. This study will enrol over 9000 patients from all over the UK. Half of the patients will receive chemotherapy for 6 months and half will receive chemotherapy for 3 months. We will be following these patients closely for many years to see if the effect of the two treatments is the same. We will also be looking at the side effects of the treatment and how this affects quality of life, and whether the cost of treatment is affected. If this study does show that 3 months of treatment is as effective as 6 months it will lead to a major change in the way bowel cancer patients are treated in future. Treatment will be shorter with fewer side effects and will be more cost effective. This will be of enormous benefit to the individual patient, healthcare providers and society at large.
Andrew Briggs (Co-Investigator)Claire Kelly (Co-Investigator)David Kerr (Co-Investigator)Jim Cassidy (Principal Investigator)Jim Paul (Co-Investigator)Timothy Iveson (Co-Investigator)
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know